{"schema":"sb.node.v1","id":"sb:e/7d813bfb49961b6a9474d861","kind":"entity","label":{"text":"g12d","locale":"en"},"identity":{"anchor":"label:en:g12d","strength":"label"},"asOf":{"knowledgeCutoff":"2026-10-10T19:00:35.865848+00:00","snapshot":"deploy b663cc8b34a8931137d702b8e11a6acd5fab341d"},"lens":{"kind":"public"},"build":{"plane":"projected","builtFrom":["entity_graph.slim.json","entity_receipts (deploy asset)","event_graph.json","truth_records (deploy asset)","corroborated_record.json"],"rule":"node-projection.entity@v1"},"standing":{"evidence":{"supporting":75,"separatePublishers":42,"basis":"documents that mention the subject and the outlets that carried them; a mention is evidence the referent is in use, not evidence about any claim","receiptsOnTopic":{"state":"measured","share":0.853,"named":64,"of":75,"basis":"documents whose own title or summary lead names the subject, over every counted document that mentions it anywhere (the entity graph's measurement); receipts are drawn from the former only"}},"admission":{"state":"provisional","reason":"entity graph provenance 'observed'; the node carries no promotion receipt in v1","policy":"EQ-PROMOTION (receipt not carried)"},"disposition":{"state":"served","reason":"public record"},"validity":{"from":"2026-04-12","to":"2026-10-09","basis":"first and last day we saw it mentioned; not the subject's own lifetime"},"measurement":{"state":"partial","blind":["assertion coverage 0.213: about 79% of mentions carry no typed assertion"]}},"dimensions":{"domains":["oncology","kras_research"],"activeDays":49,"assertions":{"launch-release":10,"regulatory-approval":5,"acquisition":1}},"up":[],"upNote":"An entity is a root: it is contained by nothing. Pan out by following R.","children":{"count":6,"byKind":{"observation":6},"withheld":{"state":"withheld","count":6,"reason":"6 receipts withheld: no source link (the same rule the topic record applies)"},"items":[{"id":"sb:o/3368fe705730c6b5ba31802d","kind":"observation","label":"Endpoints News · 2026-09-29 · Merck licenses a KRAS G12D inhibitor for $400M upfront","url":"https://endpoints.news/merck-licenses-a-kras-g12d-inhibitor-for-400m-upfront/"},{"id":"sb:o/413157e22d252c26dbd9d615","kind":"observation","label":"Fierce Biotech · 2026-09-28 · Merck pens $2.1B deal with China’s SciBrunch to chase KRAS G12D","url":"https://www.fiercebiotech.com/biotech/merck-pens-21b-deal-chinas-scibrunch-chase-kras-g12d"},{"id":"sb:o/f7395ddac517f6ec1c07da82","kind":"observation","label":"Cancer Cell · 2026-09-16 · Chemotherapy-free phase 1/2 trial of HRS-4642 plus adebrelimab in previously treated metastatic KRAS G12D-mutant pancreatic cancer.","url":"https://doi.org/10.1016/j.ccell.2026.08.012"},{"id":"sb:o/c4b5e391cfb75edbdaf8c614","kind":"observation","label":"Nat Med · 2026-09-15 · Oral KRAS G12D inhibitor GFH375 for previously treated advanced solid tumors with KRASG12D mutations: a phase 1 trial.","url":"https://doi.org/10.1038/s41591-026-04559-4"},{"id":"sb:o/41df8d3833505d4562f793a0","kind":"observation","label":"bioRxiv · 2026-09-15 · Hras G12V induces follicular thyroid cancer with attenuated MAPK activation and increased latency compared to Kras G12D.","url":"https://doi.org/10.64898/2026.09.09.750413"},{"id":"sb:o/1d2e49536424a7e8dba8e940","kind":"observation","label":"J Med Chem · 2026-09-10 · Discovery of Highly Efficacious CRBN-Based KRAS Degraders Targeting Cancers with KRAS G12D and G12V Mutations.","url":"https://doi.org/10.1021/acs.jmedchem.6c01153"}],"cursor":null,"order":"newest first; we keep the 6 newest receipts for this entity whose own title or summary lead (the entity graph's test) names it. Its other observations are counted in standing.evidence.supporting but are not addressable in v1"},"relations":{"count":6,"byKind":{"co-mentioned":6},"items":[{"kind":"relation","label":"co-mentioned with kras (74 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/3c25303808c8dcd5bc600407"},{"kind":"relation","label":"co-mentioned with pancreatic cancer (18 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/c78c767b1b2cf72289f62d46"},{"kind":"relation","label":"co-mentioned with colorectal cancer (17 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/cd17eca01cd8632fb2903bed"},{"kind":"relation","label":"co-mentioned with lung cancer (15 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/848dbb8ea2e2589bac9cba88"},{"kind":"relation","label":"co-mentioned with pdac (10 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/9b442e69b38c5e940101ab3d"},{"kind":"relation","label":"co-mentioned with solid tumors (9 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/be70d60c1e55f9367cf80f7d"}],"cursor":null,"order":"situations first, then claims (the subject's own maintained record, then site-wide corroborated clusters; each label ends with its standing), then co-mentions by shared documents, descending. Co-mentions are the ten strongest the entity graph keeps per entity"},"edge":{"state":"continues"},"links":{"rest":"/api/v1/node/e/7d813bfb49961b6a9474d861","mcp":"traverse {\"id\":\"sb:e/7d813bfb49961b6a9474d861\"}","page":"/entity/g12d/"},"limits":{"levelsPerCall":1,"pageSize":10,"maxPageSize":50,"membersMax":50,"statement":"One level per call: depth is 1 and only 1, and there is no whole-graph dump. pageSize 1-50 (default 10); a page limit is a cursor, never an edge. Members are listed up to 50. At most 60 traverse calls a minute per caller (runaway-loop protection, not a meter). One knowledge cutoff is served: the deploy's."},"actions":[{"verb":"unfold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/7d813bfb49961b6a9474d861\",\"level\":\"children\"}"},{"verb":"fold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/7d813bfb49961b6a9474d861\"}"},{"verb":"panOut","lit":false,"effect":"read","layer":"cantina","reason":"An entity is a root: it is contained by nothing. Pan out by following R."},{"verb":"follow","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/7d813bfb49961b6a9474d861\",\"level\":\"relations\"}"},{"verb":"receipts","lit":false,"effect":"read","layer":"cantina","reason":"receipts are the observations below this node; unfold to reach them"},{"verb":"edge","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/7d813bfb49961b6a9474d861\"}"},{"verb":"asOf","lit":false,"effect":"read","layer":"cantina","reason":"v1 serves one knowledge cutoff, this deploy's; walking an earlier cutoff needs retained history (EQ-REPLAY), which v1 does not keep"},{"verb":"switchObserver","lit":false,"effect":"read","layer":"cantina","reason":"the public record is the same for every observer; traversal through a Watch's lens is not served in v1"},{"verb":"readOriginal","lit":false,"effect":"read","layer":"cantina","reason":"no translation is applied on this node; every label is the source's own text"},{"verb":"save","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"saving applies to a configured Watch; configure one around this node first (free), then save it"},{"verb":"deliver","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"delivery applies to a saved Watch"},{"verb":"format","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"output format applies to a saved Watch"},{"verb":"deltaR","lit":false,"effect":"read","layer":"workshop","reason":"Delta R needs a saved Watch with a previous reading"},{"verb":"read","lit":false,"effect":"read","layer":"docking-bay","reason":"one-time Reads are parked until the Commander decides their shape (#938)"}]}